02268nas a2200265   4500000000100000008004100001100001700042700001300059700001600072700001600088700001900104700001300123700001500136700001500151700001400166700001700180700001300197700001900210700001600229700001300245700001900258245012900277520158200406022001401988       2017                            d1 aIslam Sheikh1 aFeng Zhe1 aLi Hua-Long1 aBei Wei-Jie1 aGuo Xiao-Sheng1 aWang Kun1 aYi Shi-Xin1 aLuo De-Mou1 ada Li Xi-1 aChen Shi-Qun1 aRan Peng1 aChen Peng-Yuan1 aChen Ji-Yan1 aLiu Yong1 aZhou Ying-Ling00aAssociation of lipoprotein(a) with long-term mortality following coronary angiography or percutaneous coronary intervention.3 a<p>
<b>BACKGROUND: </b>There is no consistent evidence to suggest the association of plasma lipoprotein(a) (Lp[a]) with long-term mortality in patients undergoing coronary angiography (CAG) or percutaneous coronary intervention (PCI).
</p>

<p>
<b>HYPOTHESIS: </b>Level of Lp(a) is associated with long-term mortality following CAG or PCI.
</p>

<p>
<b>METHODS: </b>We enrolled 1684 patients with plasma Lp(a) data undergoing CAG or PCI between April 2009 and December 2013. The patients were divided into 2 groups: a low-Lp(a) group (Lp[a] &lt;16.0 mg/dL; n = 842) and a high-Lp(a) group (Lp[a] ≥16.0 mg/dL; n = 842).
</p>

<p>
<b>RESULTS: </b>In-hospital mortality was not significantly different between the high and low Lp(a) groups (0.8% vs 0.5%, respectively; P = 0.364). During the median follow-up period of 1.95 years, the high-Lp(a) group had a higher long-term mortality than did the low-Lp(a) group (5.8% vs 2.5%, respectively; P = 0.003). After adjustment of confounders, multivariate Cox regression analysis revealed that a higher Lp(a) level was an independent predictor of long-term mortality (hazard ratio: 1.96, 95% confidence interval: 1.07-3.59, P = 0.029).
</p>

<p>
<b>CONCLUSIONS: </b>Our data suggested that an elevated Lp(a) level was significantly associated with long-term mortality following CAG or PCI. However, additional larger multicenter studies will be required to investigate the predictive value of Lp(a) levels and evaluate the benefit of controlling Lp(a) levels for patients undergoing CAG or PCI.
</p>
  a1932-8737